Search

Your search keyword '"Solman L"' showing total 27 results
Start Over Author "Solman L"
27 results on '"Solman L"'

2. Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey*

Author

Wedgeworth, E., Glover, M., Irvine, A. D., Neri, I., Baselga, E., Clayton, T. H., Beattie, P. E., Bjerre, J. V., Burrows, N. P., Foelster-Holst, R., Hedelund, L., Hernandez-Martin, A., Audrain, H., Bhate, K., Brown, S. J., Baryschpolec, S., Darne, S., Durack, A., Dvorakova, V., Gach, J., Goldstraw, N., Goodyear, H., Grabczynska, S., Greenblatt, D., Halpern, J., Hearn, R. M.R., Hoey, S., Hughes, B., Jayaraj, R., Johansson, E. K., Lam, M., Leech, S., OʼRegan, G. M., Morrison, D., Porter, W., Ramesh, R., Schill, T., Shaw, L., Taylor, A. E.M., Taylor, R., Thomson, J., Tiffin, P., Tsakok, M., Janmohamed, S. R., Laguda, B., McPherson, T., Oranje, A. P., Patrizi, A., Ravenscroft, J. C., Shahidullah, H., Solman, L., Svensson, A., Wahlgren, C. F., Hoeger, P. H., and Flohr, C.

Published
2016
Full Text
View/download PDF

16. 使用普萘洛尔治疗IH的BSPD指南

Author

Solman, L., primary, Glover, M., additional, Beattie, P.E., additional, Buckley, H., additional, Clark, S., additional, Gach, J.E., additional, Giardini, A., additional, Helbling, I., additional, Hewitt, R.J., additional, Laguda, B., additional, Langan, S.M., additional, Martinez, A.E., additional, Murphy, R., additional, Proudfoot, L., additional, Ravenscroft, J., additional, Shahidullah, H., additional, Shaw, L., additional, Syed, S.B., additional, Wells, L., additional, and Flohr, C., additional

Published
2018
Full Text
View/download PDF

17. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines

Author

Solman, L., primary, Glover, M., additional, Beattie, P.E., additional, Buckley, H., additional, Clark, S., additional, Gach, J.E., additional, Giardini, A., additional, Helbling, I., additional, Hewitt, R.J., additional, Laguda, B., additional, Langan, S.M., additional, Martinez, A.E., additional, Murphy, R., additional, Proudfoot, L., additional, Ravenscroft, J., additional, Shahidullah, H., additional, Shaw, L., additional, Syed, S.B., additional, Wells, L., additional, and Flohr, C., additional

Published
2018
Full Text
View/download PDF

18. BSPD guidelines for treatment of IH with propranolol

Author

Solman, L., primary, Glover, M., additional, Beattie, P.E., additional, Buckley, H., additional, Clark, S., additional, Gach, J.E., additional, Giardini, A., additional, Helbling, I., additional, Hewitt, R.J., additional, Laguda, B., additional, Langan, S.M., additional, Martinez, A.E., additional, Murphy, R., additional, Proudfoot, L., additional, Ravenscroft, J., additional, Shahidullah, H., additional, Shaw, L., additional, Syed, S.B., additional, Wells, L., additional, and Flohr, C., additional

Published
2018
Full Text
View/download PDF

20. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.

Author

Ahmed, A., Solman, L., and Williams, H. C.

Subjects
*ATOPIC dermatitis, *CHILDREN, *ALLERGIES, *AGE groups, *DRUG therapy
Abstract

Summary: Aim: To assess the efficacy and safety of crisaborole ointment, a phosphodiesterase 4 inhibitor, for the treatment of mild or moderate atopic dermatitis (AD) in two phase III studies (AD‐301 and AD‐302). Design and setting: Two identically designed multicentre, double‐blind randomized controlled trials were conducted in the U.S.A. Participants were randomized 2 : 1 to receive crisaborole or vehicle treatment. In total 47 and 42 investigational centres were identified for AD‐301 and AD‐302, respectively. Study participants: Inclusion criteria were identified as age ≥ 2 years, clinical diagnosis of AD (as per the Hanifin and Rajka criteria), ≥ 5% body surface area involvement, and baseline Investigator's Static Global Assessment (ISGA) mild or moderate. Exclusion criteria included previous use of biologics or systemic corticosteroids (within the last 28 days) or a topical calcineurin inhibitor/corticosteroid (within the last 14 days), and active skin infection. Exposures: Participants were instructed to apply the study drug twice daily to all lesions identified at baseline, and all new lesions identified after day 1 (with weekly review of application instructions). Bland emollients were permitted to be used on skin not treated with the study drug. Primary outcome: The primary outcome was defined as ISGA clear or almost clear at day 29, with a 2‐grade or more improvement from baseline. Outcomes: Secondary outcomes included the proportion of patients with an ISGA score of clear or almost clear at day 29, and time to success in ISGA score. Additional outcomes included pruritus severity and signs of AD (erythema, exudation, excoriation, induration/papulation and lichenification), and were measured on a 4‐point scale (none, mild, moderate, severe). Adverse events were also recorded. Results: More participants in the crisaborole‐treated group achieved ISGA scores of clear or almost clear with ≥ 2‐grade improvement than in the vehicle‐treated group (AD‐301, 32·8% vs. 25·4%, P = 0·38; AD‐302, 31·4% vs. 18·0%, P < 0·001). Greater percentages of clear and almost clear scores were observed in the treatment groups (51·7% vs. 40·6%, P = 0·005; 48·5% vs. 29·7%; P < 0·001), as well as earlier success in ISGA score and improvement in pruritus (P ≤ 0·001). No serious treatment‐related adverse events were identified. Conclusions: Based on the study results, the authors suggest that crisaborole is a safe treatment that improves disease severity, pruritus and clinical signs associated with AD. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

21. A survey of the treatment and management of patients with severe chronic spontaneous urticaria.

Author

Ho, B., Heelan, K., Solman, L., Jones, R., Dua, J., Ingram, J. R., and Flohr, C.

Abstract

The article discusses a 2019 survey of the treatment of patients with severe chronic spontaneous urticaria (CSU) in Great Britain. Topics covered include the condition's manifestations and usual management, the common use of omalizumab and ciclosporin as first-line agents, and the varying prescriptions of agents by dermatology, allergy, and immunology consultants. Also noted is the prime barrier of potential adverse effects (AE) in prescribing systemic medications.

Published
2019
Full Text
View/download PDF

27. Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey

Author

S Baryschpolec, S. Darne, T McPherson, K Bhate, Grainne M. O'Regan, R. M. Ross Hearn, J Halpern, Annalisa Patrizi, J V Bjerre, N. Goldstraw, J Thomson, L Shaw, R Jayaraj, Eulalia Baselga, P.H. Hoeger, M. Glover, Arnold P. Oranje, A Hernandez-Martin, Timothy H Clayton, M Tsakok, B. Laguda, L Hedelund, Åke Svensson, Carsten Flohr, Jane Ravenscroft, R Taylor, Sara J. Brown, Regina Foelster-Holst, Isabella Neri, Nigel Burrows, D Morrison, Veronika Dvorakova, E Wedgeworth, T Schill, P Tiffin, A. Durack, Alan D. Irvine, S. Leech, S Hoey, Aileen Taylor, S. Grabczynska, B Hughes, L Solman, R Ramesh, Carl-Fredrik Wahlgren, David J. Greenblatt, H Audrain, M Lam, E K Johansson, H. Shahidullah, P.E. Beattie, Sherief R. Janmohamed, W Porter, J. E. Gach, H Goodyear, Wedgeworth, E., Glover, M., Irvine, A.D., Neri, I., Baselga, E., Clayton, T.H., Beattie, P.E., Bjerre, J.V., Burrows, N.P., Foelster-Holst, R., Hedelund, L., Hernandez-Martin, A., Audrain, H., Bhate, K., Brown, S.J., Baryschpolec, S., Darne, S., Durack, A., Dvorakova, V., Gach, J., Goldstraw, N., Goodyear, H., Grabczynska, S., Greenblatt, D., Halpern, J., Hearn, R.M.R., Hoey, S., Hughes, B., Jayaraj, R., Johansson, E.K., Lam, M., Leech, S., O'Regan, G.M., Morrison, D., Porter, W., Ramesh, R., Schill, T., Shaw, L., Taylor, A.E.M., Taylor, R., Thomson, J., Tiffin, P., Tsakok, M., Janmohamed, S.R., Laguda, B., Mcpherson, T., Oranje, A.P., Patrizi, A., Ravenscroft, J.C., Shahidullah, H., Solman, L., Svensson, A., Wahlgren, C.F., Hoeger, P.H., Flohr, C, Faculty of Medicine and Pharmacy, Skin function and permeability, Surgical clinical sciences, and Dermatology

Subjects
Male, Pediatrics, medicine.medical_specialty, Skin Neoplasms, Treatment outcome, Administration, Oral, Antineoplastic Agents, Dermatology, Propranolol, Hemangioma, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, 030225 pediatrics, Skin Neoplasms/drug therapy, Medicine, Humans, Dose-Response Relationship, Drug, Hemangioma/drug therapy, business.industry, Infant, medicine.disease, Antineoplastic Agents/administration & dosage, body regions, First line treatment, Treatment Outcome, Multicenter study, Female, Propranolol/administration & dosage, business, medicine.drug
Abstract

Summary Background Oral propranolol is widely prescribed as first-line treatment for infantile haemangiomas (IHs). Anecdotally, prescribing practice differs widely between centres. Objectives The Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce was founded to establish patterns of use of propranolol in IHs. Methods Participating centres entered data on all of their patients who had completed treatment with oral propranolol for IHs, using an online data capture tool. Results The study cohort comprised 1097 children from 39 centres in eight European countries. 76·1% were female and 92·8% had a focal IH, with the remainder showing a segmental, multifocal or indeterminate pattern. The main indications for treatment were periocular location (29·3%), risk of cosmetic disfigurement (21·1%) and ulceration and bleeding (20·6%). In total 69·2% of patients were titrated up to a maintenance regimen, which consisted of 2 mg kg−1 per day (85·8%) in the majority of cases. 91·4% of patients had an excellent or good response to treatment. Rebound growth occurred in 14·1% upon stopping, of whom 53·9% were restarted and treatment response was recaptured in 91·6% of cases. While there was no significant difference in the treatment response, comparing a daily maintenance dose of < 2 mg kg−1 vs. 2 mg kg−1 vs. > 2 mg kg−1, the risk of adverse events was significantly higher: odds ratio (OR) 1 vs. adjusted OR 0·70, 95% confidence interval (CI) 0·33–1·50, P = 0·36 vs. OR 2·38, 95% CI 1·04–5·46, P = 0·04, Ptrend < 0·001. Conclusions The PITCH survey summarizes the use of oral propranolol across 39 European centres, in a variety of IH phases, and could be used to inform treatment guidelines and the design of an interventional study.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results